Protagonist Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Protagonist Therapeutics hat ein Gesamteigenkapital von $531.9M und eine Gesamtverschuldung von $0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $603.9M bzw. $71.9M. Protagonist Therapeutics Das EBIT des Unternehmens beträgt $149.1M, so dass der Zinsdeckungsgrad -6.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $468.7M.

Wichtige Informationen

0%

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad-6.3x
BargeldUS$468.72m
EigenkapitalUS$531.92m
GesamtverbindlichkeitenUS$71.94m
GesamtvermögenUS$603.86m

Jüngste Berichte zur Finanzlage

Recent updates

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PTGXDie kurzfristigen Aktiva des Unternehmens ($476.8M) übersteigen seine kurzfristigen Passiva ($44.6M).

Langfristige Verbindlichkeiten: PTGXDie kurzfristigen Vermögenswerte des Unternehmens ($476.8M) übersteigen seine langfristigen Verbindlichkeiten ($27.4M).


Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PTGX ist schuldenfrei.

Schulden abbauen: PTGX hatte vor 5 Jahren keine Schulden.

Schuldendeckung: PTGX hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: PTGX hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.


Bilanz


Entdecken Sie finanziell stabile Unternehmen